FLT3-ITDhigh is a driver mutation that presents with a high leukemic burden, confers a poor prognosis, and has a significant negative impact on the management of patients with AML [1, 6, 9, 17–19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.